A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians by Ruperto, Nicolino et al.
RESEARCH Open Access
A randomized, double-blind, placebo-controlled
trial of paracetamol and ketoprofren lysine salt
for pain control in children with
pharyngotonsillitis cared by family pediatricians
Nicolino Ruperto
1*, Luigi Carozzino
2, Roberto Jamone
2, Federico Freschi
2, Gianfranco Picollo
2, Marcella Zera
2,
Ornella Della Casa Alberighi
3, Enrica Salvatori
4, Alessandra Del Vecchio
4, Paolo Dionisio
4 and Alberto Martini
5
Abstract
Background: To evaluate the analgesic effect and tolerability of paracetamol syrup compared to placebo and
ketoprofen lysine salt in children with pharyngotonsillitis cared by family pediatricians.
Methods: A double-blind, randomized, placebo-controlled trial of a 12 mg/kg single dose of paracetamol
paralleled by open-label ketoprofren lysine salt sachet 40 mg. Six to 12 years old children with diagnosis of
pharyngo-tonsillitis and a Children’s Sore Throat Pain (CSTP) Thermometer score > 120 mm were enrolled. Primary
endpoint was the Sum of Pain Intensity Differences (SPID) of the CSTP Intensity scale by the child.
Results: 97 children were equally randomized to paracetamol, placebo or ketoprofen. Paracetamol was significantly
more effective than placebo in the SPID of children and parents (P < 0.05) but not in the SPID reported by
investigators, 1 hour after drug administration. Global evaluation of efficacy showed a statistically significant
advantage of paracetamol over placebo after 1 hour either for children, parents or investigators. Patients treated in
open fashion with ketoprofen lysine salt, showed similar improvement in pain over time. All treatments were well-
tolerated.
Conclusions: A single oral dose of paracetamol or ketoprofen lysine salt are safe and effective analgesic
treatments for children with sore throat in daily pediatric ambulatory care.
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Background
Treatment of acute pain, particularly in pediatric popu-
lation, should be a priority for clinicians. In the past,
pain has been underestimated and sometimes under-
treated in children, probably due to individual and social
attitudes toward pain and the complexity of its assess-
ment in children [1-3]. Nowadays, the importance of
pain control in the pediatric population is widely recog-
nized. However, there is still a lack of adequate clinical
trials assessing the pharmacological effects of the oral
analgesics commonly used in pediatric daily primary
care [3,4].
Paracetamol (acetaminophen) is currently one of the
most popular and widely used analgesic and antipyretic
in children for the symptomatic treatment of acute pain
and fever. Differently from non-steroidal anti-inflamma-
tory drugs (NSAIDs), paracetamol does not produce
gastrointestinal damage or untoward cardio-renal effects.
On the other hand, its anti-inflammatory activity is neg-
ligible [5].
Aim of this trial was to evaluate and confirm the
analgesic effect and the tolerability of a paracetamol
syrup formulation administered at the dosage of 12 mg/
kg in children with pharyngotonsillitis. The study was
carried out in double-blind conditions in comparison to
placebo and controlled, in an open fashion, with keto-
profen lysine salt 40 mg as the positive control.
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Study design
The study design was a randomized, double-blind, paral-
lel group, placebo-controlled trial of 12 mg/kg single
dose paracetamol syrup with an open label comparison
with ketoprofen lysine salt sachet 40 mg as the positive
control over three days.
Study setting and population
Between March 2006 and May 2007, the study was set
in five pediatric primary care public ambulatories of the
Italian national net of family pediatricians. The protocol
was approved by the Ethics Committee and parents and
children signed the approved informed consent form as
appropriate.
T h o s ee l i g i b l ew e r e6 - 1 2y e a r - o l dw i t hd i a g n o s i so f
pharyngo-tonsillitis confirmed by a score > 5 in the
Tonsillo-Pharyngitis Scale (TPS) [6], a score > 120 mm
in the Children’s Sore Throat Pain (CSTP) Thermo-
meter [6], and a maximum 1-week disease duration.
Subjects were excluded from the study if they had posi-
tive history of hypersensitivity or allergy to the study
medications, other conditions know to interfere with
assigned drugs, or if they used any antipyretic drugs or
throat lozenges in the past 6 hours, and/or analgesics or
any “cold” medication in the past 8 hours.
Study treatments
After consent and baseline assessments, children were
randomly assigned to 1 of the 3 groups (Figure 1). The
first and second groups received a single administration
of paracetamol syrup 12 mg/kg (Tachipirina
® syrup
2 . 4 % ,A C R A FS p A ) ,c o r r e s p o n d i n gt o1m L / 2k go f
body weight or placebo syrup (1 mL/2 kg of body
weight) in a double blind fashion. The third group was
assigned, to open label to ketoprofen lysine salt 40 mg
(Oki
® 80 mg granules for oral suspension, half sachet,
Dompè SpA) in order to have an indirect comparison
with a widely used analgesic in Italy. A double dummy
design was not forecast for technical and logistical rea-
sons. No further dosing was allowed in the following 4
hours. After the clinical assessments by the family pedia-
trician, patients assigned in a double blind fashion to the
syrup (active or placebo) received a bottle of paraceta-
mol for the home management of pain. The paraceta-
mol dosage to be used was 12 mg/kg up to 4-5 times
daily, and ketoprofen 40 mg (half 80 mg sachet) every 8
hours for a maximum of 3 administrations daily. The
paracetamol 12 mg/kg single dose was chosen on the
basis of the therapeutic range of 10-15 mg/kg widely
recognized as effective in the treatment of fever and
pain control [7] while the ketoprofen lysine salt dosage
was the same as recommended in its own Summary of
Product Characteristics.
There was one randomization sequence computer
generated via Microsoft Access 2000. A pre-assigned list
with progressive numbering was provided to each inves-
tigator. The double-blind conditions were obtained
using paracetamol matching placebo syrup, including
matching external box and internal opaque bottle. Keto-
profen lysine salt was not masked due to manufacturing
issues, and was provided in sachets as per the current
Italian marketing authorization.
Outcome measures
Three assessments of pain intensity were performed at
the primary care facilities (baseline, 30 minutes and 1
hour after treatment), and three at home (2, 3 and 4
hours after treatment). On day 4 children came back to
their family pediatrician office for final visit assessment.
At baseline, the investigators assessed the patient’s
medical history, physical examination, concomitant
treatments, and underwent a rapid antigen detection
testing (Testpack Plus Strep-A OBC II
®, Abbott). In
case of positive findings on the test, an appropriate anti-
biotic for the treatment of streptococcal infection was
prescribed. The pediatrician evaluated the severity of
tonsillo-pharyngitis by the TPS a 0-3 categorical scale
(score range 0-21) considering 7 clinical parameters:
body temperature, tonsils’ volume, pharyngeal’ colour,
enanthema, size, number and sensibility of anterior cer-
vical lymph node. Children completed the CSTP ther-
mometer as proposed by Schachtel et al [6], a vertical
paper drawn 0-200 mm thermometer with anchoring
words no pain (0 mm) and very severe pain (200 mm),
divided at 10 mm intervals; the child was asked to swal-
low and to “color in the pain thermometer so that it
shows how much your throat hurts now” At all fixed
times, the child was also asked to indicate pain intensity
using the horizontal five-faces of the Children’sS o r e
Throat Relief Scale (CSTRS) in the version proposed by
Schachtel et al [6]; this scale consisted of a series of five
Figure 1 Flow diagram of the progress of enrolled patients
through the trial.
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Page 2 of 7faces, from “no relief” on the left to “complete relief” on
the right.
Before assigning the treatment, pain intensity was also
independently rated by the investigator and parent
(usually the mother) using the Sore Throat Pain Inten-
sity (STPI), a 0-100 mm VAS, with anchoring words no
pain (child has no difficulty in deglutition at 0 mm) and
very severe pain (child has a lot of difficulties in degluti-
tion at 100 mm) [6].
Both the investigator and parent evaluated pain inten-
sity at 30 min and 1 hour after dosing, by the STPI
Scale, while the child used the CSTP Intensity Scale.
Using the same scale, the child and the parent also
assessed at home pain intensity at 2, 3, and 4 hours
after treatment. At day 4 after treatment period, a final
visit was performed by the family pediatrician in its
office to re-evaluate the patient’s clinical conditions.
Efficacy was also evaluated by parent and investigator
on a 5 levels categorical scale (very good, good, fair,
poor or very poor) and by children on a 3 levels catego-
rical scale (a lot, little or none).
In addition 1 hour after treatment, and at the final
visit, the investigator verified the occurrence of adverse
events during the study period and judged tolerability
using a 5-point scale (from very good to very poor). Tol-
erability was also assessed by the parent at 1 and 4
hours after treatment.
The use of the CSTP Thermometer, and of the
CSTRS happy-sad faces for efficacy were explained by
the family pediatrician to the child by using pre-printed
color images for adequate training. Training was also
offered to the parent for the use of the STPI and overall
efficacy and tolerability categorical scales. Both the child
and the parent completed their baseline pain assessment
before randomization and drug assignment. All inter-
vention including physical examination, additional medi-
cation assessment scale were prospectively documented
on ad hoc designed 3 carbon copy paper case report
forms monitored by the Pediatric Clinical Trial Office of
the G. Gaslini hospital.
Statistics
The study complied with the Consolidated Standards of
Reporting Trials (CONSORT) statement and used the
intention-to-treat population for analysis [8-10].
Ketprofen lysine salt was used in open conditions as
the positive control. Thus, comparisons between the
group treated in open label and double blinded groups
were descriptive in nature and no formal statistical com-
parison were performed with ketoprofen lysine salt [11].
Descriptive statistics were reported in terms of means
and standard deviation (SD) or with 95% confidence
intervals (95% CI) for quantitative variables and in terms
of absolute frequencies and percentages for qualitative
variables.
The following efficacy parameters were evaluated: Pain
Intensity Difference (PID) calculated at each time by
subtracting the baseline (CSTP and STPI) pain intensity
score from the actual pain intensity score, Sum of Pain
Intensity Differences (SPID) and Total Pain Relief
(TOTPAR) estimated as the Area Under the Curve
(AUC).
The analysis of variance was used to evaluate SPID
and TOTPAR comparing paracetamol to placebo. SPID
of CSTP Intensity scale was the primary study endpoint.
All efficacy evaluations were analyzed by the Cochran-
Mantel-Haenszel test comparing paracetamol to placebo.
All the tests were two sided and a p value < 0.05 was
considered statistically significant.
The sample size calculation was based on the results
reported in a study comparing ibuprofen suspension (10
mg/kg) and paracetamol (15 mg/kg) to placebo in chil-
dren with sore throat [6]. Sixty patients (30 patients per
group) were adequate to detect a difference between
paracetamol and placebo of 59 in SPID of CSTP Inten-
sity scale, assuming a standard deviation of 88.8, using a
two group t-test with a 0.05 one-sided significance level,
a n dap o w e rh i g h e rt h a n8 0 % .Ag r o u po f3 0p a t i e n t s
treated with ketoprofen lysine salt was included in the
trial as active control.
Results
Patient Enrollment and Baseline characteristics
Ninety-seven Caucasian school children (55 males and
42 females) with pharyngotonsillitis were recruited.
Thirty-two were assigned to paracetamol, 32 to placebo,
and 33 to ketoprofen lysine salt (Figure 1). Two patients,
initially randomized in the placebo and ketoprofen
group, had a subsequent episode of pharyngotonsillitis,
were both randomly re-allocated in the paracetamol
group but were excluded from the analysis.
Table 1 shows the demographic characteristics and
mean baseline (SD) scores assessing the severity of phar-
yngotonsillitis and pain..
Efficacy and safety evaluation over time of paracetamol
versus placebo
Figure 2 shows the results of primary outcome of the
study, the time course of pain in each treatment group,
as assessed by children with the CSTP. Paracetamol was
significantly more effective than placebo in the SPID of
children (two tailed 95%CI paracetamol-placebo, from
-151.3 to -15.3, p = 0.0171). Similar results for the com-
parison paracetamol versus placebo were obtained when
pain was assessed by children with of TOTPAR of the
five-faces of the CSTRS (p = 0.0039).
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ment as reported by the SPID as measured by the STPI
of parents (panel A) and investigators (panel B), respec-
tively. Paracetamol was significantly more effective than
placebo in the SPID of parents (p = 0.0008), while no
differences between paracetamol and placebo were
detected in the SPID reported by investigators.
Table 2 shows the overall categorical efficacy evalua-
tion by children, parents and investigators at different
time points. After 1 hour from dosing, a statistically sig-
nificant advantages of paracetamol over placebo were
detected in the judgement reported by children, parents
and investigators. These results were confirmed in the
at home assessment performed by children and parents,
4 hours from dosing and after 4-days.
Efficacy evaluation over time of ketoprofen lysine salt
The efficacy of open-label ketoprofen-treated patients
group, was similar to paracetamol, and definitely differ-
ent from placebo (Figure 2, 3 and Table 2).
Safety evaluations
Safety evaluations at 1, 4 hours after administration was
rated good or very good by parents, investigators and
children in more than 90% of the cases for both parace-
tamol and placebo. No serious adverse events occurred.
Four adverse events were observed in 4 patients: bron-
chitis and rash in the ketoprofen lysine salt group, diar-
rhoea and cough in the placebo group; none of the
event were related to the administered drugs or placebo.
Blinding
No patients or physicians were unblinded to the parace-
tamol or placebo treatment.
Discussion
In this randomised double blind trial children treated
with paracetamol showed greater improvement in pain
over time with respect to placebo-treated subjects, with
similar effects observed in the open label ketoprofen-
treated group.
In the past, the use of analgesics in the pediatric field
was not fully adequate especially because parents were
often under the misapprehension that analgesic drugs
could have been harmful [12,13]. Pain is a part of life
and effective analgesia in relation to the intensity of suf-
fering should be provided either in the hospital setting,
ambulatory care and home. The assessment and treat-
ment of pain are meaningful parts of pediatric practice
and analgesic drugs have been effectively used so far in
neonates, infants and children [1,2]. However, the lack
of adequate drug pediatric labeling and clinical trials in
children called both the Food and Drug Administration
Table 1 Children disposition and demographics at baseline.
paracetamol (n = 32) placebo (n = 32) ketoprofen (n = 33) total (n = 97)
Males n (%) 20 (62.5%) 17 (53.1%) 18 (54.5%) 55 (56.7%)
Positive Strep-test (%) 16 (50.0) 15 (46.9) 15 (45.4) 46 (47.4)
mean (SD) mean (SD) mean (SD) mean (SD)
Age (years) 8.6 (1.9) 8.1 (1.7) 8.3 (1.9) 8.3 (1.8)
Height (cm) 133.8 (11.3) 132.7 (11.4) 133.3 (12.4) 133.3 (11.6)
Weight (kg) 30.7 (8.5) 30.0 (8.0) 33.9 (13.1) 31.6 (10.2)
TPS (0-21 points) 10.9 (2.1) 11.4 (2.8) 10.6 (2.9) 11.0 (2.6)
Temperature (°C) 37.7 (0.7) 37.9 (0.9) 38.0 (0.8) 37.8 (0.8)
CSTPI (0-200 mm VAS) 157.4 (17.3)
a 158.2 (20.2) 158.2 (17.1)
b 157.9 (18.1)
c
STPI-parents (0-100 mm VAS) 63.3 (9.9) 63.9 (13.9) 64.1 (10.2) 63.8 (11.3)
STPI-investigators (0-100 mm VAS) 67.3 (11.5) 68.9 (14.4) 69.7 (12.1) 68.6 (12.6)
CSTPI = Children’s Sore Throat Pain Intensity; STPI = Sore Throat Pain Intensity; TPS = Tonsillo-Pharyngitis Score
a) n = 31; b) n = 32; c) n = 95
Figure 2 M e a n( 9 5 %C I )c h a n g eo v e rt i m ec o u r s eo fp a i na s
assessed by children with the Children’s Sore Throat Pain
(CSTP) Thermometer with values going from 0 mm (no pain)
to 200 mm (very severe pain). P values refers to the as Sum of
Pain Intensity Differences (SPID) with 95% CI for the comparison
paracetamol versus placebo.
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legislative intervention with the aims to facilitate studies
in children [14-16] and establish pediatric network
[17-19]. This framework helped to facilitate the conduct
this trial in the ambulatory care setting thanks to the
Italian national wide net of family pediatrician.
In this double-blind, placebo-controlled clinical trial a 12
mg/Kg dosage of paracetamol in syrup was tested in
children suffering of sore throat due to pharyngotonsillitis,
and using as active control ketoprofen lysine salt adminis-
t e r e di na no p e nf a s h i o n .T h eafter treatment analgesic
effect was independently assessed by the investigator for 1
hour, and by child and parent for 4 hours using validated
tools for the assessment of pain relief [6,20]. Both active
drugs (paracetamol and ketoprofen lysine salt) were more
effective than placebo in reducing sore throat, as reported
Figure 3 Mean (95% CI) change over time course of pain as assessed by parents (Panel A) or investigators (Panel B) with the Sore
Throat Pain Intensity (STPI) with values going from 0 mm (no difficulty in deglutition) to 100 mm (a lot of difficulties in deglutition).
P values refers to the as Sum of Pain Intensity Differences (SPID) with 95% CI for the comparison paracetamol versus placebo.
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differences between paracetamol and placebo were
detected by investigators. This discrepancy may be related
to the shorter period of the investigators’ observation (1
hour only against the 4 hours of children and parents) and
to the known discrepancy in physicians versus parents/
children assessment [21-23]. Neverthless, when analgesic
efficacy was evaluated using categorical scales, a statisti-
cally significant effect of paracetamol over placebo was
detected by children, parents and investigators. The
analgesic effect of ketoprofen was similar to that observed
with paracetamol. Tolerability of both drug was very good
with only four minor adverse events were reported, 2 in
the ketoprofen group and 2 in the placebo group.
The analgesic efficacy of paracetamol in the treatment
of pain in children is widely recognized, even if few con-
sistent experiences are available in literature. Schachtel
et al rated ibuprofen and acetaminophen (at 15 mg/kg)
as significantly effective compared with placebo (p <
0.05) in children with acute sore throat under double-
blind, placebo-controlled conditions [6]. Bertin et al
found that ibuprofen but not paracetamol (at 10 mg/kg)
was superior to placebo on day 2 for pain control in a
double blind placebo-controlled trial in children with
otitis media [24] or pharyngitis [25]. Hamalainen et al
[26] found that ibuprofen was twice as likely as acetami-
nophen to abort migraine within 2 hours versus placebo
in their double blind trial. The meta-analysis by Perrott
et al [27] showed that in children, single doses of ibu-
profen (4-10 mg/kg) and acetaminophen (7-15 mg/kg)
have similar efficacy for relieving moderate to severe
pain, and similar safety as analgesics or antipyretics.
More recently, Clark et al in a trial with a partial
blinded randomisation, found that ibuprofen was super-
ior to paracetamol, or codein for acute pain relief in
children with musculoskeletal trauma referred to a pae-
diatric emergency department [13].
Conclusions
In conclusion, this study confirm that a single oral dose
of paracetamol or ketoprofen lysine salt are safe and
effective analgesic treatments for children with sore
throat in daily pediatric ambulatory care.
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